Karp Capital Management’s Akero Therapeutics AKRO Stock Holding History

Karp Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-35,000	Closed	-$331K	–	122
2022 Q2	$331K	Hold	35,000	–	–	0.06%	115
2022 Q1	$497K	Hold	35,000	–	–	0.07%	97
2021 Q4	$740K	Sell	35,000 -2,005	-5%	-$44.5K	0.09%	94
2021 Q3	$827K	Buy	+37,005	New	+$838K	0.12%	105

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

YCM

Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Karp Capital Management's AKRO Position: Q3 2022 in Review

Karp Capital Management sold out of Akero Therapeutics (AKRO) in Q3 2022, closing a stake of 35,000 shares — an estimated $331K sold.

Karp Capital Management first reported a position in AKRO in Q3 2021 and held it in 4 quarters. The position peaked at $827K in Q3 2021. 146 funds tracked by Wall St. Rank hold AKRO as of Q3 2022.

Karp Capital Management reported no remaining Akero Therapeutics position as of Q3 2022 after selling out during the quarter.
Karp Capital Management sold 35,000 Akero Therapeutics shares in Q3 2022, an estimated $331K.
Karp Capital Management first reported a position in Akero Therapeutics in Q3 2021 and held it in 4 quarters.
Karp Capital Management's Akero Therapeutics position peaked at $827K in Q3 2021.
146 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2022.

Based on Karp Capital Management's 13F filing for Q3 2022, filed 18 Oct 2022.